European Society of Cardiology Overhauls Heart Failure Guidelines
The European Society of Cardiology published updated heart failure guidelines on August 28, 2026, overhauling clinical management standards across Europe. ad-hoc-news.de reported that the new rulebook dissolves the intermediate category for heart failure with mildly reduced ejection fraction. Under the revised framework, clinicians now split the condition into two primary categories based on a left ventricular ejection fraction threshold of 50 percent.
Patients with an ejection fraction from 41 to 49 percent formerly occupied the intermediate category known as HFmrEF. The latest guidelines reclassify this specific patient group under heart failure with reduced ejection fraction, which now spans any value below 50 percent. Heart failure with preserved ejection fraction remains defined at 50 percent or higher. This structural shift aims to simplify diagnostic pathways for practicing physicians dealing with complex cardiovascular presentations.
Stricter Prescribing Rules for Sacubitril and Valsartan
Despite the broader grouping for reduced ejection fraction, the guidelines urge caution regarding specific pharmaceutical treatments. ad-hoc-news.de noted that the ESC warns against unconsidered off-label use of Entresto, which combines sacubitril and valsartan. Critical trial data from the PARADIGM-HF study established clinical benefits strictly for patients suffering from symptomatic chronic heart failure with a left ventricular ejection fraction of 40 percent or less.
Prescribing the medication to individuals with an ejection fraction above 40 percent constitutes formal off-label use under the new directives. To protect physicians from financial recourse demands by health insurance funds, the society demands comprehensive documentation. Medical files must include precise ICD-10 coding, continuous tracking of severity via the New York Heart Association classification, exact ejection fraction measurements, and current kidney function markers.
Mandatory Kidney Screenings and Cardiorenal Connections
The guidelines establish mandatory systematic screenings for chronic kidney disease across all patients with prior cardiovascular conditions. ad-hoc-news.de reported that this diagnostic protocol requires determining the estimated glomerular filtration rate alongside recurring albuminuria measurements. This synchronized monitoring reflects the formal integration of the cardiovascular-kidney-metabolic syndrome into everyday clinical practice.
For patients diagnosed with diabetic kidney disease, the expert panel recommends targeted co-prescriptions. Combining finerenon and empagliflozin serves as a validated nephroprotective and cardioprotective measure designed to slow combined organ deterioration. These recommendations move chronic disease management away from isolated laboratory values toward interdisciplinary organ care.
Defining the new ejection fraction threshold for heart failure treatment
What exact ejection fraction threshold defines the newly expanded reduced ejection fraction category?
The updated guidelines define heart failure with reduced ejection fraction as any left ventricular ejection fraction below 50 percent, absorbing the former 41 to 49 percent intermediate bracket.
Which specific clinical trial supports the prescribing boundaries for sacubitril and valsartan?
The PARADIGM-HF trial established the clinical benefit of the medication strictly for patients with a left ventricular ejection fraction of 40 percent or lower.
What renal diagnostics are now mandatory for cardiovascular patients under the 2026 guidelines?
Physicians must conduct systematic screenings using the estimated glomerular filtration rate and recurring albuminuria measurements for all individuals with cardiovascular pre-existing conditions.